Platelet Aggregation and Adenosine Diphosphate/Adenosine Triphosphate Receptors: A Historical Perspective

ABSTRACT

The work of many investigators since adenosine diphosphate (ADP) was recognized as a platelet aggregating agent in 1961 has led to an appreciation of the important part that ADP plays in hemostasis and thrombosis. Recently, interest has focused on the platelet receptors for ADP and adenosine triphosphate (ATP). Platelets are unique because they have two P2Y receptors that must act in concert to achieve a normal aggregation response. The P2Y₁ receptor is responsible for mobilizing internal calcium, platelet shape change, and weak aggregation. The P2Y₁₂ receptor inhibits adenylyl cyclase, but the concentration of cyclic AMP is reduced only if it has been raised from its low basal levels by stimulation of adenylyl cyclase by an aggregation inhibitor such as adenosine or prostaglandin I₂. The abnormal bleeding of the rare patients whose platelets lack P2Y₁₂ and the beneficial clinical effects of ticlopidine and clopidogrel that block this receptor indicate that P2Y₁₂, in addition to inhibiting adenylyl cyclase, may have an as yet unidentified role that is needed for its cooperative aggregation effect with P2Y₁. ATP stimulates a rapid influx of calcium into platelets through the P2X₁ receptor, and it may synergize with ADP when these two nucleotides are released from platelets at a site of vessel injury.

Platelet aggregation - platelet receptors - ADP receptors - ADP inhibitors - clopidogrel

REFERENCES

• 1 Hellem A J. The adhesiveness of human blood platelets in vitro.  Scand J Clin Lab Invest. 1960;  12(suppl 51) 1-117
• 2 Gaarder A, Jonsen J, Laland S, Hellem A J, Owren P A. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets.  Nature. 1961;  192 531-532
• 3 Mustard J F, Packham M A. Factors influencing platelet function: adhesion, release, and aggregation.  Pharmacol Rev. 1970;  22 97-187
• 4 Born G VR. Observations on the change in shape of blood platelets brought about by adenosine diphosphate.  J Physiol. 1970;  209 487-511
• 5 Zucker M B, Jerushalmy Z. Studies on platelet shape and aggregation; effect of inhibitors on these and other platelet characteristics. In: Johnson SA, Seegers WH Physiology of Hemostasis and Thrombosis Springfield, IL; Charles C Thomas 1967: 249-265
• 6 Born G VR, Cross M J. The aggregation of blood platelets.  J Physiol. 1963;  168 178-195
• 7 Ardlie N G, Perry D W, Packham M A, Mustard J F. Influence of apyrase on stability of suspensions of washed rabbit platelets.  Proc Soc Exp Biol Med. 1971;  136 1021-1022
• 8 Kinlough-Rathbone R L, Perry D W, Rand M L, Packham M A. Most apyrase preparations are impure and contain inhibitors of cathepsin G: suggestions for use of apyrase in preparation and stabilization of platelet suspensions.  Thromb Haemost. 1999;  81 849-850
• 9 Grette K. Studies on the mechanism of thrombin-catalyzed hemostatic reactions in blood platelets.  Acta Physiol Scand. 1962;  195(suppl) 1-93
• 10 Hovig T. Release of a platelet-aggregating substance (adenosine diphosphate) from rabbit blood platelets induced by saline “extract of tendons”.  Thromb Diath Haemorrh. 1963;  9 264-278
• 11 Holmsen H, Weiss H J. Hereditary defect in the platelet release reaction caused by a deficiency in the storage pool of platelet adenine nucleotides.  Br J Haematol. 1970;  19 643-649
• 12 D'Souza L, Glueck H I. Measurement of nucleotide pools in platelets using high pressure liquid chromatography.  Thromb Haemost. 1977;  38 990-1001
• 13 Holmsen H, Day H J. Adenine nucleotides and platelet function.  Ser Haematol. 1971;  4 28-58
• 14 Marcus A J, Broekman M J, Drosopoulos H J et al.. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.  J Clin Invest. 1997;  99 1351-1360
• 15 Zimmermann H. Nucleotides and cd39: principal modulatory players in hemostasis and thrombosis.  Nat Med. 1999;  5 987-988
• 16 Kinlough-Rathbone R L, Mustard J F. Synergism of agonists. In: Holmsen H Platelet Responses and Metabolism, Vol. I Boca Raton, FL; CRC Press 1986: 193-207
• 17 Ware J A, Smith M, Salzman E W. Synergism of platelet-aggregating agents. Role of elevation of cytoplasmic calcium.  J Clin Invest. 1987;  80 267-271
• 18 Kinlough-Rathbone R L, Perry D W, Guccione M A, Rand M L, Packham M A. Degranulation of human platelets by the thrombin receptor peptide SFLLRN: comparison with degranulation by thrombin.  Thromb Haemost. 1993;  70 1019-1023
• 19 Cattaneo M, Canciani M T, Lecchi A et al.. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates.  Blood. 1990;  75 1081-1086
• 20 Trumel C, Payrastre B, Plantavid M et al.. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR-1 activating peptide through late activation of phosphoinositide 3-kinase.  Blood. 1999;  94 4156-4165
• 21 Holmsen H, Weiss H J. Further evidence for a deficient storage pool of adenine nucleotides in platelets from some patients with thrombocytopathia-“storage pool disease”.  Blood. 1972;  39 197-209
• 22 Born G VR. Aggregation of blood platelets by adenosine diphosphate and its reversal.  Nature. 1962;  194 927-929
• 23 O'Brien J R. Platelet aggregation. Part II. Some results from a new method of study.  J Clin Pathol. 1962;  15 452-455
• 24 Haslam R J. Mechanisms of blood platelet aggregation. In: Johnson SA, Seegers WH Physiology of Hemostasis and Thrombosis Springfield, IL; Charles C Thomas 1967: 88-112
• 25 Born G VR. Uptake of adenosine and of adenosine diphosphate by human blood platelets.  Nature. 1965;  206 1121-1122
• 26 Salzman E W, Ashford T P, Chambers D A, Neri L L. Platelet incorporation of labelled adenosine and adenosine diphosphate.  Thromb Diath Haemorrh. 1969;  22 304-315
• 27 Skoza L, Zucker M B, Jerushalmy Z, Grant R. Kinetic studies of platelet aggregation induced by adenosine diphosphate and its inhibition by chelating agents, guanidino compounds and adenosine.  Thromb Diath Haemorrh. 1967;  18 713-775
• 28 Mills D CB, Smith J B. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3′:5′-cyclic monophosphate in platelets.  Biochem J. 1971;  121 185-196
• 29 Haslam R J, Rosson G M. Aggregation of human blood platelets by vasopressin.  Am J Physiol. 1972;  223 958-967
• 30 Macfarlane D E, Mills D CB. The effects of ATP on platelets: evidence against the central role of released ADP in primary aggregation.  Blood. 1975;  46 309-320
• 31 Plow E F, Haas T A, Byzova T V. Platelet receptors: fibrinogen. In: Gresele P, Page CP, Fuster V, Vermylen J Platelets in Thrombotic and Non-Thrombotic Disorders Cambridge, UK; Cambridge University Press 2002: 188-203
• 32 Dorsam R T, Kim S, Jin J, Kunapuli S P. Coordinated signaling through both G_12/13 and G_i pathways is sufficient to activate GPIIb/IIIa in human platelets.  J Biol Chem. 2002;  277 47588-47595
• 33 Haslam R J, Cusack N J. Blood platelet receptors for ADP and for adenosine. In: Burnstock G Purinergic Receptors. Receptors and Recognition, Series B, Volume 12 London; Chapman and Hall 1981: 221-285
• 34 Mills D CB. ADP receptors on platelets.  Thromb Haemost. 1996;  76 835-856
• 35 Cusack N J, Hourani S MO. Platelet P2 receptors: from curiosity to clinical targets.  J Auton Nerv Syst. 2000;  81 37-43
• 36 Born G VR, Cross M J. Effect of adenosine diphosphate on the concentration of platelets in circulating blood.  Nature. 1963;  197 974-976
• 37 Packham M A, Rand M L, Kinlough-Rathbone R L. Aggregation. In: Gresele P, Page CP, Fuster V, Vermylen J Platelets in Thrombotic and Non-Thrombotic Disorders Cambridge, UK; Cambridge University Press 2002: 338-356
• 38 Smith J B. Prostaglandins in platelet aggregation and haemostasis. In: Bloom AL, Thomas DP Haemostasis and Thrombosis. 2nd ed Edinburgh; Churchill Livingstone 1987: 78-89
• 39 Lages B, Weiss H J. Dependence of human platelet functional responses on divalent cations: aggregation and secretion in heparin- and hirudin-anticoagulated platelet-rich plasma and the effect of chelating agents.  Thromb Haemost. 1981;  45 173-179
• 40 Packham M A, Bryant N L, Guccione M A, Kinlough-Rathbone R L, Mustard J F. Effect of the concentration of Ca²⁺ in the suspending medium on the responses of human and rabbit platelets to aggregating agents.  Thromb Haemost. 1989;  62 968-976
• 41 Cattaneo M, Gachet C, Cazenave J -P, Packham M A. Adenosine diphosphate (ADP) does not induce thromboxane A₂ generation in human platelets.  Blood. 2002;  99 3868-3869
• 42 Zucker M B, Peterson J. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion.  Proc Soc Exp Biol Med. 1968;  127 547-551
• 43 Weiss H J, Aledort L M, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man.  J Clin Invest. 1968;  47 2169-2180
• 44 Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
• 45 Mills D CB, Smith J B. The control of platelet responsiveness by agents that influence cyclic AMP metabolism.  Ann NY Acad Sci. 1972;  201 391-399
• 46 Cole B, Robison G A, Hartmann R C. Studies on the role of cyclic AMP in platelet function.  Ann NY Acad Sci. 1971;  185 477-487
• 47 Salzman E W, Levine L. Cyclic 3′,5′-adenosine monophosphate in human blood platelets. II. Effect of N⁶-2'-0-dibutyryl cyclic 3′,5′-adenosine monophosphate on platelet function.  J Clin Invest. 1971;  50 131-141
• 48 Haslam R J. Interactions of the pharmacological receptors of blood platelets with adenylate cyclase.  Ser Haematol. 1973;  6 333-350
• 49 Yang J, Wu J, Jiang H et al.. Signaling through G_i family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors.  J Biol Chem. 2002;  277 46035-46042
• 50 Macfarlane D E, Mills D CB. Inhibition by ADP of prostaglandin induced accumulation of cyclic AMP in intact human platelets.  J Cyclic Nucleotide Res. 1981;  7 1-11
• 51 Maffrand J P, Eloy F. Synthesis of thioenopyridines and furopyridines of therapeutic interest.  Eur J Med Chem. 1974;  9 483-486
• 52 Savi P, Pereillo J M, Uzabiaga M F et al.. Identification and biological activity of the active metabolite of clopidogrel.  Thromb Haemost. 2000;  84 891-896
• 53 Bruno J J, Molony B A. Ticlopidine. In: Scriabine A New Drugs Annual: Cardiovascular Drugs. New York; Raven Press 1983: 295-316
• 54 Gachet C. ADP receptors of platelets and their inhibition.  Thromb Haemost. 2001;  86 222-232
• 55 Gachet C, Cattaneo M, Ohlmann P et al.. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors.  Br J Haematol. 1995;  91 434-444
• 56 Hechler B, Eckly A, Ohlmann P, Cazenave J -P, Gachet C. The P2Y₁ receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel.  Br J Haematol. 1998;  103 858-866
• 57 Gachet C, Cazenave J -P. ADP induced blood platelet activation: a review.  Nouv Rev Fr Hematol. 1991;  33 347-358
• 58 Macfarlane D E, Mills D CB, Srivastava P C. Binding of 2-azidoadenosine [β-³²P]diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase.  Biochemistry. 1982;  21 544-549
• 59 Macfarlane D E, Srivastava P C, Mills D CB. 2-methylthioadenosine[β-³²P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets.  J Clin Invest. 1983;  71 420-428
• 60 Nurden P, Savi P, Heilmann E et al.. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function.  J Clin Invest. 1995;  95 1612-1622
• 61 Bennett J S, Colman R F, Colman R W. Identification of adenine nucleotide binding proteins in human platelet membranes by affinity labeling with 5′-p-fluorosulfonylbenzoyl adenosine.  J Biol Chem. 1978;  253 7346-7354
• 62 Colman R W. Aggregin: a platelet ADP receptor that mediates activation.  FASEB J. 1990;  4 1425-1435
• 63 Cristalli G, Mills D CB. Identification of a receptor for ADP on blood platelets by photoaffinity labelling.  Biochem J. 1993;  291 875-881
• 64 Ralevic V, Burnstock G. Receptors for purines and pyrimidines.  Pharmacol Rev. 1998;  50 413-492
• 65 Woulfe D, Yang J, Brass L. ADP and platelets: the end of the beginning.  J Clin Invest. 2001;  107 1503-1505
• 66 Ohlmann P, Laugwitz K-L, Nürnberg B et al.. The human platelet ADP receptor activates G_i2 proteins.  Biochem J. 1995;  312 775-779
• 67 Jantzen H M, Milstone D S, Gousset L, Conley P B, Mortensen R M. Impaired activation of murine platelets lacking Gα_i2 .  J Clin Invest. 2001;  108 477-483
• 68 Cattaneo M, Lecchi A, Randi A M, McGregor J L, Mannucci P M. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate.  Blood. 1992;  80 2787-2796
• 69 Hollopeter G, Jantzen H-M, Vincent D et al.. Identification of the platelet ADP receptor targeted by antithrombotic drugs.  Nature. 2001;  409 202-207
• 70 Foster C J, Prosser D M, Agans J M et al.. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.  J Clin Invest. 2001;  107 1591-1598
• 71 Torti M, Lapetina E G. Roles of phospholipase C and phospholipase D in receptor-mediated platelet activation. In: Gresele P, Page CP, Fuster V, Vermylen J Platelets in Thrombotic and Non-Thrombotic Disorders. Cambridge, UK; Cambridge University Press 2002: 238-259
• 72 Offermanns S, Toombs C F, Hu Y-H, Simon M I. Defective platelet activation in Gα_q-deficient mice.  Nature. 1997;  389 183-186
• 73 Léon C, Hechler B, Freund M et al.. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y₁ receptor-null mice.  J Clin Invest. 1999;  104 1731-1737
• 74 Fabre J E, Nguyen M, Latour A et al.. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y₁-deficient mice.  Nat Med. 1999;  5 1199-1202
• 75 Gabbeta J, Vaidyula V R, Dhanasekaran D N, Rao A K. Human platelet Gαq deficiency is associated with decreased Gαq gene expression in platelets but not neutrophils.  Thromb Haemost. 2002;  87 129-133
• 76 Jin J, Kunapuli S P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.  Proc Natl Acad Sci U S A. 1998;  95 8070-8074
• 77 Tsien R Y, Pozzan T, Rink T J. Measuring and manipulating cytosolic Ca²⁺ with trapped indicators.  Trends Biochem Sci. 1984;  9 263-266
• 78 Rink T J, Sage S O. Calcium signaling in human platelets.  Annu Rev Physiol. 1990;  52 431-449
• 79 MacKenzie A B, Mahaut-Smith M P, Sage S O. Activation of receptor-operated cation channels via P_2X1 not P_2T purinoceptors in human platelets.  J Biol Chem. 1996;  271 2879-2881
• 80 Vial C, Hechler B, Léon C, Cazenave J -P, Gachet C. Presence of P2X₁ purinoceptors in human platelets and megakaryoblastic cell lines.  Thromb Haemost. 1997;  78 1500-1504
• 81 Daniel J L, Dangelmaier C, Jin J et al.. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets.  J Biol Chem. 1998;  273 2024-2029
• 82 Mahaut-Smith M P, Ennion S J, Rolf M G, Evans R J. ADP is not an agonist at P2X₁ receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets.  Br J Pharmacol. 2000;  131 108-114
• 83 Oury C, Toth-Zsamboki E, Thys C et al.. The ATP-gated P2X₁ ion channel acts as a positive regulator of platelet responses to collagen.  Thromb Haemost. 2001;  86 1264-1271
• 84 Rolf M G, Brearley C A, Mahaut-Smith M P. Platelet shape change evoked by selective activation of P2X₁ purinoceptors with α,β-methylene ATP.  Thromb Haemost. 2001;  85 303-308
• 85 Vial C, Pitt S J, Roberts J et al.. Lack of evidence for functional ADP-activated human P2X₁ receptors supports a role for ATP during hemostasis and thrombosis.  Blood. 2003;  102 3646-3651
• 86 Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts M F. P2X₁-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen.  Blood. 2002;  100 2499-2505
• 87 Oury C, Kuijpers M JE, Toth-Zsamboki E et al.. Overexpression of the platelet P2X₁ ion channel in transgenic mice generates a novel prothrombotic phenotype.  Blood. 2003;  101 3969-3976
• 88 Hechler B, Lenain N, Marchese P et al.. A role of the fast ATP-gated P2X₁ cation channel in thrombosis of small arteries in vivo.  J Exp Med. 2003;  198 661-667
• 89 Gordon J L. Extracellular ATP: effects, sources and fate.  Biochem J. 1986;  233 309-319
• 90 Hourani S MO, Welford L A, Cusack N J. Effects of 2-methylthioadenosine 5′β,γ-methylenetriphosphonate and 2-ethylthioadenosine 5′-monophosphate on human platelet aggregation induced by adenosine 5′-diphosphate.  Drug Dev Res. 1996;  38 12-23
• 91 Léon C, Hechler B, Vial C et al.. The P2Y₁ receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells.  FEBS Lett. 1997;  403 26-30
• 92 Boyer L, Romero-Avila T, Schachter J B, Harden T K. Identification of competitive antagonists of the P2Y₁ receptor.  Mol Pharmacol. 1996;  50 1323-1329
• 93 Jin J, Daniel J L, Kunapuli S P. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets.  J Biol Chem. 1998;  273 2030-2034
• 94 Hechler B, Léon C, Vial C et al.. The P2Y₁ receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation.  Blood. 1998;  92 152-159
• 95 Savi P, Beauverger P, Labouret C et al.. Role of P2Y₁ purinoceptor in ADP-induced platelet activation.  FEBS Lett. 1998;  422 291-295
• 96 Baurand A, Raboisson P, Freund M et al.. Inhibition of platelet function by administration of MRS2179, a P2Y₁ receptor antagonist.  Eur J Pharmacol. 2001;  412 213-221
• 97 Hoffmann C, Moro S, Nicholas R A, Harden T K, Jacobson K A. The role of amino acids in extracellular loops of the human P2Y₁ receptor in surface expression and activation processes.  J Biol Chem. 1999;  274 14639-14647
• 98 Cattaneo M. The platelet P2Y receptors as targets for new antithrombotic drugs.  J Thromb Haemost. 2003;  1 1133-1135
• 99 Fagura M S, Dainty I A, McKay G D et al.. P2Y₁-receptors in human platelets which are pharmacologically distinct from P2Y_ADP-receptors.  Br J Pharmacol. 1998;  124 157-164
• 100 Wang L, Östberg O, Wihlborg A -K et al.. Quantification of ADP and ATP receptor expression in human platelets.  J Thromb Haemost. 2003;  1 330-336
• 101 Cattaneo M. Inherited platelet-based bleeding disorders.  J Thromb Haemost. 2003;  1 1628-1636
• 102 Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti M L. Platelets from a patient heterozygous for the defect of P2_cyc receptors for ADP have a secretion defect despite normal thromboxane A₂ production and normal granule stores: further evidence that some cases of platelet ‘primary secretion defect' are heterozygous for a defect of P2_cyc receptors.  Arterioscler Thromb Vasc Biol. 2000;  20 e101-e106
• 103 Cattaneo M, Lombardi R, Zighetti M L et al.. Deficiency of (³³P)2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A₂ production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A₂ production.  Thromb Haemost. 1997;  77 986-990
• 104 Oury C, Lenaerts T, Peerlinck K, Vermylen J, Hoylaerts M F. Congenital deficiency of the phospholipase C coupled platelet P2Y1 receptor leads to a mild bleeding disorder.  Thromb Haemost. 1999;  (suppl) 20-21
• 105 Oury C, Toth-Zsamboki E, Van Geet C et al.. A natural dominant negative P2X1 receptor due to deletion of a single amino acid residue.  J Biol Chem. 2000;  275 22611-22614
• 106 Rao A K. Inherited defects in platelet signaling mechanisms.  J Thromb Haemost. 2003;  1 671-681
• 107 Baurand A, Eckly A, Bari N et al.. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y₁ and P2cyc receptors.  Thromb Haemost. 2000;  84 484-491
• 108 Enjyoji K, Sévigny J, Lin Y et al.. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation.  Nat Med. 1999;  5 1010-1017
• 109 Adam F, Verbeuren T J, Fauchère J -L, Guillin M -C, Jandrot-Perrus M. Thrombin-induced platelet PAR4 activation: role of glycoprotein Ib and ADP.  J Thromb Haemost. 2003;  1 798-804
• 110 Lenain N, Freund M, Léon C, Cazenave J -P, Gachet C. Inhibition of localized thrombosis in P2Y₁-deficient mice and rodents treated with MRS2179, a P2Y₁ receptor antagonist.  J Thromb Haemost. 2003;  1 1144-1149